Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22(+) B-acute lymphoblastic leukemia patients: a phase II study

导出原文传递

翻译打印收藏纠错

作者： Chevallier, Patrice ^[1] ; Huguet, Francoise ^[2] ; Raffoux, Emmanuel ^[3] ; Etienne, Anne ^[4] ; Leguay, Thibaut ^[5] ; Isnard, Francoise ^[6] ; Robillard, Nelly ^[7] ; Guillaume, Thierry ^[8] ; Delaunay, Jacques ; Charbonnier, Aude ; Pigneux, Arnaud ; Peterlin, Pierre ; Bene, Marie C. ; Wegener, William A. ; Goldenberg, David M. ; Dombret, Herve

作者单位： CHU, Dept Hematol, Bordeaux, France ^[1] Immunomedics Inc, Morris Plains, NJ USA ^[2] Hop St Antoine, Dept Hematol, F-75571 Paris, France ^[3] CHU Hotel Dieu, Hematol Biol Dept, Nantes, France ^[4] Hop St Louis, Dept Hematol, Paris, France ^[5] Inst Paoli Calmette, Dept Hematol, Marseille, France ^[6] CHU Hotel Dieu, Dept Hematol, Nantes, France ^[7] CHU, Dept Hematol, Toulouse, France ^[8]

发布时间 2015-08-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Haematologica

2015年100卷4期

E128-E131页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22(+) B-acute lymphoblastic leukemia patients: a phase II study

Haematologica

相似文献

Haematologica

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22(+) B-acute lymphoblastic leukemia patients: a phase II study

Haematologica

相似文献

Haematologica

相关期刊

检索历史清除